Your browser is no longer supported. Please, upgrade your browser.
SNY Sanofi daily Stock Chart
Index- P/E23.68 EPS (ttm)1.82 Insider Own16.40% Shs Outstand2.59B Perf Week1.39%
Market Cap111.78B Forward P/E13.16 EPS next Y3.28 Insider Trans0.00% Shs Float2.32B Perf Month7.44%
Income4.69B PEG3.38 EPS next Q- Inst Own10.70% Short Float0.26% Perf Quarter4.83%
Sales37.04B P/S3.02 EPS this Y2.20% Inst Trans-0.81% Short Ratio3.20 Perf Half Y8.55%
Book/sh23.87 P/B1.81 EPS next Y6.49% ROA- Target Price49.00 Perf Year15.23%
Cash/sh- P/C- EPS next 5Y7.00% ROE- 52W Range36.11 - 43.72 Perf YTD6.73%
Dividend1.66 P/FCF- EPS past 5Y-4.50% ROI6.80% 52W High-1.28% Beta1.02
Dividend %3.85% Quick Ratio- Sales past 5Y-0.20% Gross Margin69.20% 52W Low19.52% ATR0.61
Employees115631 Current Ratio1.60 Sales Q/Q94.10% Oper. Margin18.80% RSI (14)68.52 Volatility0.92% 1.20%
OptionableYes Debt/Eq0.32 EPS Q/Q105.00% Profit Margin13.60% Rel Volume0.97 Prev Close43.54
ShortableYes LT Debt/Eq0.29 EarningsFeb 08 BMO Payout0.00% Avg Volume1.86M Price43.16
Recom1.70 SMA205.02% SMA506.41% SMA2007.90% Volume1,811,565 Change-0.87%
Nov-07-16Initiated Goldman Neutral
Sep-23-16Initiated Piper Jaffray Neutral
Sep-15-16Resumed JP Morgan Underweight
Sep-13-16Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-16Upgrade Berenberg Hold → Buy
May-03-16Downgrade HSBC Securities Buy → Hold
Dec-10-15Downgrade Exane BNP Paribas Neutral → Underperform
Dec-01-15Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-15Downgrade Bernstein Outperform → Mkt Perform
Oct-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Feb-20-17 09:06AM  Sanofis Unique Foothold in Diabetes and Cardiovascular
07:37AM  This Keeps Driving Sanofis Growth
Feb-19-17 11:41AM  Could Celgene Have Another Billion-Dollar Blockbuster on Its Hands? at Motley Fool
Feb-17-17 04:46PM  Inside Sanofis Revenues in 4Q16
09:07AM  Parsabiv Is Expected to Boost Amgens Revenues in 2017
07:44AM  Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta
Feb-16-17 09:20AM  Why Amgen's Becoming One of My Top Dividend Stocks to Buy at Motley Fool
06:16AM  Sanofi Backtracked on Actelion Offer Price Amid J&J Talks at Bloomberg
04:50AM  How Sanofi lost out to J&J in $30 bln battle for Actelion Reuters
Feb-15-17 12:49PM  Amicus Therapeutics Updates Migalastat Drug at Investopedia
08:31AM  Amgen Looking to Broaden Leukemia Drug Blincyto's Label
Feb-13-17 10:00AM  Sanofi to Sell 5 OTC Drugs to Ipsen for $88M at Investopedia
Feb-12-17 09:48PM  Sanofi nears deal to sell some over-the-counter drugs to Ipsen - Bloomberg Reuters
08:07PM  Sanofi Nears Agreement to Sell Some Over-the-Counter Drugs to Ipsen: Source
Feb-10-17 12:00PM  Sanofi :SNY-US: Earnings Analysis: 2016 By the Numbers : February 10, 2017
11:30AM  Sanofi -- Moody's: Pipelines are biggest credit quality hope for Europe's Pharma sector in 2017 at Moody's
06:44AM  Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi
Feb-09-17 05:16PM  While Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever
04:56PM  Regeneron Defies Light Q4 Sales, Eylea Outlook On Amgen-Rivaling LDL Win
03:34PM  Alnylam Pharmaceuticals, Inc. Presents Progress -- Investors Dig It at Motley Fool
01:11PM  Regeneron Pharmaceuticals Inc (REGN) and Sanofi SA (ADR) (SNY) Obtain Suspension of Injunction for Cholesterol Drug Sales at Insider Monkey
11:09AM  Regeneron (REGN) Misses on Q4 Earnings & Sales, View Bleak
11:04AM  European stocks set for 13-day high as SocGen, Total march higher
10:56AM  Judge Lifts Ban on Amgen Cholesterol Drug Rival at Investopedia
08:33AM  Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now
08:17AM  A Heart-Stopping Patent Injunction Stay For Sanofi at Forbes
Feb-08-17 07:02PM  [$$] Appeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug at The Wall Street Journal
05:33PM  Regeneron, Sanofi Temporarily Stave Off Ban Of Amgen-Rivaling LDL-Buster
05:30PM  Appeals Court Grants Stay of Permanent Injunction for Praluent® (alirocumab) During Appeals Process PR Newswire
04:49PM  Federal appeals court decision will keep Regeneron/Sanofi drug at center of patent dispute on market, for now at MarketWatch
04:21PM  Allergan Leads Drug Stocks On View-Crushing Q4, 2016, 2017 Guidance
12:23PM  Oil shares decline but European market pulls out a win at the close at MarketWatch
09:48AM  [$$] Sanofi points to lower profit for 2017 at Financial Times
08:08AM  [$$] Sanofi Seeks Cure for FDA Concerns at French Factory at The Wall Street Journal
07:30AM  Sanofi Delivers 2016 Sales and Business EPS Growth at CER PR Newswire
06:15AM  European stocks rise, but Maersk sinks after cutting dividend
05:00AM  Sanofi meets 4Q profit forecasts
03:25AM  Drugmaker Sanofi sees weak 2017 earnings, not in hurry for M&A
03:02AM  Sanofi CEO Interview - FY 2016 Results (video) PR Newswire
01:30AM  Sanofi Plant, Key to New Drugs, Wins Tentative U.S. Backing at Bloomberg
Feb-07-17 09:45AM  Better Buy: Agenus Inc. vs. Alnylam Pharmaceuticals, Inc. at Motley Fool
Feb-03-17 04:24PM  Amgen's LDL-Buster Boosts The Medicines Co., But Regeneron Slides
08:46AM  Good News and Bad News for MannKind Corporation at Motley Fool
Feb-02-17 06:50PM  [$$] Amgen Sees Positive Results in Repatha Study at The Wall Street Journal
04:58PM  Amgen Crushes Q4 Views, But Sees Light 2017 Sales; Repatha Tops CV Study
02:59PM  MannKind Looks to Boost Flagging Afrezza Sales at Investopedia
01:10PM  Sanofi Genzyme head weighs in on drug price debate at
Feb-01-17 03:45PM  Amgen Repatha Sales Surge Past Praluent After Ban at Investopedia
03:05PM  Weighing the Foreign Exchange Impact on Novartiss Revenues in 4Q16
08:00AM  Sanofi's Xyzal® Allergy 24HR Approved for Over-the-Counter Use in the United States PR Newswire
07:50AM  SanofiRegeneron Sarilumab Approved in Canada for Arthritis
02:00AM  Sanofi Appoints Hugo Fry as General Manager UK PR Newswire
01:00AM  Regeneron and Sanofi Announce First Approval of Kevzara (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients by Health Canada PR Newswire
Jan-31-17 08:00AM  Sanofi Pasteur Announces the Availability of Quadracel DTaP-IPV Vaccine for Children 4 Through 6 Years of Age in the U.S. PR Newswire
Jan-30-17 10:06PM  Sanofi, Novo Nordisk, Lilly being sued AAP
04:18PM  Regeneron, Sanofi Could Appease LDL-Frustrated Buyers On Eczema Drug
03:58PM  The makers of insulin are being accused of price-fixing in a class-action lawsuit
03:18PM  Sanofi, Novo Nordisk and Lilly named in patients' price fixing suit Reuters
02:33PM  Hagens Berman: Insulin Manufacturers Hit with Class-Action Lawsuit over Drug Price Inflation Scheme and RICO Violations Time to Break up the Insulin Racket Business Wire
Jan-26-17 05:50PM  With new Bay Area presence, Singapore fund invests $800M in Alphabet-created Verily at
03:28PM  Here's the Reason Behind TESARO Inc.'s Sudden 12% Move Higher at Motley Fool
01:30PM  Alphabet's life science spinoff raises $800M from Singapore investor at
09:28AM  11 Largest Pharmaceutical Companies In The World at Insider Monkey
08:25AM  Drug Giants May Benefit From China Drug Inclusion at Investopedia
01:40AM  Johnson & Johnson Will Buy Actelion For $30 Billion
01:32AM  J&J to Buy Actelion for $30 Billion, Spin Off Research Unit
01:32AM  J&J Makes Big Bet on Rare Disease With $30 Billion Actelion Deal at Bloomberg
Jan-24-17 03:35PM  Is Amgens Cardiovascular Segment Still a Growth Opportunity?
Jan-23-17 12:00PM  Failed Mergers Cast Shadow on Sanofi's Future at Investopedia
11:27AM  5 Stupendously Expensive Cancer Drugs at Motley Fool
09:01AM  Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open
Jan-20-17 02:00AM  Sanofi's M&A misses frustrate some investors in drugmaker Reuters
Jan-18-17 03:56PM  MannKind Has a New Plan, but Will It Work? at Motley Fool
08:45AM  Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval
Jan-17-17 04:43PM  Regeneron, Sanofi Claim Amgen's LDL-Buster Patent Too Broad
01:22PM  Sanofi: SuliquaTM Approved in the European Union for the Treatment of Adults with Type 2 Diabetes GlobeNewswire
08:28AM  Key FDA Events to Watch Out for in Q1
Jan-16-17 09:07AM  How Did Novartis Perform in 3Q16?
08:38AM  5 Trump-Proof Pharma Dividends Up To 5.3% at Forbes
Jan-15-17 07:10AM  Why Regeneron Pharmaceuticals, Inc. Stock Slipped 32.4% in 2016 at Motley Fool
Jan-13-17 04:32PM  Odds Are Against Regeneron, Sanofi In Amgen Patent Battle: Leerink
09:30AM  Sanofi, ImmuNext Sign $500M Autoimmune Drug Pact at Investopedia
Jan-12-17 04:00PM  Insulin Drug Offers Hope for MannKind
12:04PM  Regeneron, Sanofi's Drug Manufacturing Plant Cleared at Investopedia
10:37AM  Mylans Specialty Segment: The Effect of Falling EpiPen Sales
Jan-11-17 05:05PM  Mylans EpiPen Controversy: Is It a Brand or a Generic?
Jan-10-17 06:25PM  Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases
09:30AM  The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche's, Sanofi and Regeneron Pharmaceuticals
08:53AM  2 Top Stocks in Biotech at Motley Fool
08:51AM  Amgen Inks Multiple Deals, Offers Update on Repatha Lawsuit
Jan-09-17 01:36PM  Sanofi Sees No Opening to Actelion Talks After J&J Re-Entry at Bloomberg
01:30PM  Morgan Stanley Cuts Regeneron Target On Praluent Patent Worries at
08:11AM  Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit
08:00AM  Sanofi and ImmuNext Enter into Agreement to Develop Treatments for Autoimmune Diseases PR Newswire
Jan-08-17 11:54PM  [$$] Regeneron Is Down, Not Out at The Wall Street Journal
02:02PM  Why Biotech Titans Are Clashing Over Cholesterol at Motley Fool
Jan-07-17 10:53AM  In the age of Uber and Lyft, its still hard for some Americans to get to the doctor at MarketWatch
10:47AM  Judges unusual ruling on Amgen, Regeneron patent case puts billions of dollars at stake at MarketWatch
Jan-06-17 07:33PM  Sanofi Investors Count Cost of Praluent Ruling at The Wall Street Journal
06:41PM  Why Regeneron Pharmaceuticals, Sears Holdings, and Shake Shack Slumped Today at Motley Fool
Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. It offers Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; Toujeo, an insulin glargine; and Afrezza, an inhaled insulin. The company also provides Praluent, a human monoclonal antibody; and Multaq, a multichannel blocker with anti-arrhythmic properties. In addition, it offers Cerezyme, an enzyme replacement therapy to treat gaucher disease; cerdelga, an oral therapy for Gaucher disease Type 1; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis Type 1, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for breast, prostate, gastric, lungs, and head and neck cancer treatment; Eloxatin for the treatment of stage III colon cancer; Thymoglobulin to treat acute rejection; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix/Iscover for atherothrombosis and acute coronary syndrome; Lovenox/Clexane for the treatment of venous thromboembolism; Aprovel/Avapro/Karvea for hypertension and nephropathy; Renagel/Renvela to treat chronic kidney disease; Allegra/Telfast to treat seasonal allergic rhinitis and uncomplicated hives; Stilnox/Ambien/Myslee for insomnia treatment; and Synvisc/Synvisc-One for the treatment of osteoarthritis pain. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJan 11Buy369.7187,29832,274,87223,505,694Jan 13 04:15 PM
Sanofi10% OwnerJun 14Buy363.8664,73123,552,85923,418,396Jun 16 05:47 PM